ER、PR、P53、P16和CerbB-2在乳腺癌中的表达及与临床、病理的关系

Expressions of ER ,PR ,P53,P16,CerbB-2 in breast cancer and their relationships with pathological factors

目的联合检测抑癌基因P53、P16和癌基因CerbB-2在乳腺癌中的表达情况,结合ER、PR探讨与乳腺癌发生发展及临床、病理因素之间的联系。方法采用免疫组化S-P法分别检测145例乳腺癌和10例正常乳腺组织ER、PR、P53、P16和CerbB-2蛋白的表达。结果145例乳腺癌中ER、PR、P53、P16和CerbB-2的阳性表达率分别为43.4%、40.6%、45.5%、27.5%和84.8%。与正常乳腺组织比较,P53、P16和CerbB-2的阳性表达有差异(p<0.05)。乳腺癌各病理类型之间表达没有差异(p>0.05)。ER与年龄、PR、CerbB-2、肿瘤直径、月经状态、癌周浸润相关(p<0.05);PR与ER、肿块直径、癌周浸润相关;P53与淋巴结转移个数,癌周浸润相关;P16与初潮年龄、癌周浸润相关(<0.05);CerbB-2与ER、肿瘤直径、转移淋巴结个数、月经状态、癌周浸润相关(p<0.05)。结论ER、PR是对激素治疗有价值的指标,并与P53、P16、CerbB-2等可作为评价乳腺癌的生物学行为、病理特征和预后的指标。

Objective To detect the expressions of P53, P16, CerbB-2 and ER, PR hormone receptors in breast carcinoma,and investigate their relationships with clinical and pathological factors. Methods Immunohistochemistry （S-P） method was used to detect the expressions of ER,PR,P53, P16, CerbB-2 in 145 cases of breast carcinoma and 10 cases of normal gland tissue. Results The expressions of ER,PR,P53,P16,CerbB-2 proteins in this group were 43.4%,40.6%,45.5%,27. 5%,84. 8~ respectively , It was a significant difference （p^0.01） in P53, P16, CerbB-2 between the normal tissues group and malignant group, no difference between the different histological types. ER was distinctly related to the expressions of PR, CerbB-2 and patient age, tumor diameter, menstrual status, para-tumor diffusion （p〈0.05）. PR was related to ER, tumor diameter, para-tumor diffusion. P53 was related to axillary＇g metastasis node numbers, para-tumor diffusion. P16 was related to the age of first-menstruation, para-tumor diffusion. CerbB-2 was related to ER, tumor diameter, axillary＇s＇ metastasis node numbers, para-tumor diffusion （p〈0.05）. Conclusion ER, PR are good signs for the endocrine therapy of the patients. Combined with the expressions of P53,P16 and CerbB-2,They are useful signs for the tumor prognosis and associated with the biological behaviors and pathological characteristics of the breast carcinoma.